02:45 AM EDT, 08/27/2026 (MT Newswires) -- HVIVO (HVO.L) acquired Germany-based clinical research institute CRS Clinical Research Services Berlin, according to a Thursday filing. The clinical development company paid 25,000 euros as upfront consideration. The deal also includes an earnout payment, which will be 18% of CRS Clinical Research's annual revenue for the next three years. HVIVO expects the acquisition to be immediately accretive to its earnings.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.